JMAC vs. KOD, ALT, TRML, PROK, XERS, ATXS, CRMD, RNAC, TKNO, and TERN
Should you be buying Maxpro Capital Acquisition stock or one of its competitors? The main competitors of Maxpro Capital Acquisition include Kodiak Sciences (KOD), Altimmune (ALT), Tourmaline Bio (TRML), ProKidney (PROK), Xeris Biopharma (XERS), Astria Therapeutics (ATXS), CorMedix (CRMD), Cartesian Therapeutics (RNAC), Alpha Teknova (TKNO), and Terns Pharmaceuticals (TERN). These companies are all part of the "pharmaceutical products" industry.
Maxpro Capital Acquisition vs.
Kodiak Sciences (NASDAQ:KOD) and Maxpro Capital Acquisition (NASDAQ:JMAC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations, media sentiment and community ranking.
Kodiak Sciences received 19 more outperform votes than Maxpro Capital Acquisition when rated by MarketBeat users.
Kodiak Sciences presently has a consensus price target of $8.00, indicating a potential downside of 12.28%. Given Kodiak Sciences' stronger consensus rating and higher possible upside, research analysts plainly believe Kodiak Sciences is more favorable than Maxpro Capital Acquisition.
In the previous week, Kodiak Sciences had 1 more articles in the media than Maxpro Capital Acquisition. MarketBeat recorded 1 mentions for Kodiak Sciences and 0 mentions for Maxpro Capital Acquisition. Kodiak Sciences' average media sentiment score of 0.25 beat Maxpro Capital Acquisition's score of 0.00 indicating that Kodiak Sciences is being referred to more favorably in the media.
89.1% of Kodiak Sciences shares are held by institutional investors. Comparatively, 73.2% of Maxpro Capital Acquisition shares are held by institutional investors. 45.3% of Kodiak Sciences shares are held by company insiders. Comparatively, 19.3% of Maxpro Capital Acquisition shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Kodiak Sciences has a beta of 2.38, suggesting that its share price is 138% more volatile than the S&P 500. Comparatively, Maxpro Capital Acquisition has a beta of 0.01, suggesting that its share price is 99% less volatile than the S&P 500.
Maxpro Capital Acquisition's return on equity of 0.00% beat Kodiak Sciences' return on equity.
Summary
Kodiak Sciences beats Maxpro Capital Acquisition on 9 of the 11 factors compared between the two stocks.
Get Maxpro Capital Acquisition News Delivered to You Automatically
Sign up to receive the latest news and ratings for JMAC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Maxpro Capital Acquisition Competitors List
Related Companies and Tools
This page (NASDAQ:JMAC) was last updated on 1/5/2025 by MarketBeat.com Staff